Humanin and the Receptors for Humanin

Molecular Neurobiology

Volumn 41, Issue 1, 2010, Pages 22-28

  Matsuoka, Masaaki ^a   Hashimoto, Yuichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Humanin; Humanin receptor; Neuronal cell death; Neuronal dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; CELL RECEPTOR; COLIVELIN; HUMANIN; HUMANIN RECEPTOR; NEUROPROTECTIVE AGENT; S14G HUMANIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENE MUTATION; HIPPOCAMPUS; HUMAN; MOLECULAR BIOLOGY; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; TEMPORAL CORTEX; TRANSGENIC MOUSE;

EID: 77950460128     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-009-8090-z     Document Type: Review

References (75)

1. Marx J (2007) Alzheimer's disease. Fresh evidence points to an old suspect: calcium. Science 318:384
2. Matsuoka M (2009) Humanin: a defender against Alzheimer's disease? Recent Pat CNS Drug Discov 4:37-42
3. Hashimoto Y, Niikura T, Tajima H, YasukawaT SH, Ito Y, Kita Y, Kawasumi M, Kouyama K, Doyu M, Sobue G, Koide T, Tsuji S, Lang J, Kurokawa K, Nishimoto I (2001) A. rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proc Natl Acad. Sci USA 98:6336-6341 (Pubitemid 32488239)
4. Nishimoto I, Matsuoka M, Niikura T (2004) Unravelling the role of Humanin. Trends Mol Med 10:102-105
5. Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I (2006) Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev 12:113-122 (Pubitemid 44300379)
6. Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130. Mol Biol Cell 20:2864-2873
7. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-498
8. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388
9. Hardy JA, Higgins GA (1992) Alzheimer's disease, the amyloid cascade hypothesis. Science 286:184-185
10. Hardy JA, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
11. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev Mol Cell Biol 8:101-112
12. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101:1172-1184
13. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106-113
14. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110:1129-1134
15. Sherrington R, Rogaev EI, Liang Y, Rogaeva E, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J, Bruni A, Montesi M, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky R, Wasco W, Da Silva H, Haines J, Pericak-Vance M, Tanzi R, Roses A, Fraser P, Rommens J, St George-Hyslop P (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760
16. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser P, Rommens J, St George-Hyslop P (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778
17. Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell W, Yu C, Jondro P, Schmidt S, Wang K (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-977
18. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 2:864-869 (Pubitemid 26296755)
19. Borchelt DR, Thinakaran G, Eckman CB, Lee M, Davenport F, Ratovitsky T, Prada C, Kim G, Seekins S, Yager D, Slunt H, Wang R, Seeger M, Levey A, Gandy S, Copeland N, Jenkins N, Price D, Younkin S, Sisodia S (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and. in vivo. Neuron 17:1005-1013 (Pubitemid 26424026)
20. Duff K, Eckman. C, Zehr C, Yu X, Prada C, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon M, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloidß 42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713
21. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390 (Pubitemid 28093512)
22. WolfeMS,XiaW,OstaszewskiBL,DiehlTS,KimberlyWT,SelkoeDJ(1999) Twotransmembraneaspartatesinpresenilin- 1requiredforpresenilinendoproteolysisandgamma-secretaseactivity.Nature398: 513-517(Pubitemid129523589)
23. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 25:789-791
24. Momssette DA, Parachikova. A, Green KN, LaFerla FM (2009) Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 284:6033-6037
25. Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5:340-347
26. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman B, Albert M (2000) Use of structural magnetic resonance imaging to predict who will get al.zheimer's disease. Ann Neurol 47:430-439 (Pubitemid 30194598)
27. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso M, Hallikainen M, Vanhanen M, Nissinen A, Helkala E, Vainio P, Vanninen R, Partanen K, Soininen H (2004) Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 25:303-310 (Pubitemid 38220965)
28. Becker JT, Davis SW, Hayashi KM, Becker J, Davis S, Hayashi K, Meltzer C, Toga A, Lopez O, Thompson P (2006) Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol 63:97-101 (Pubitemid 43063867)
29. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen R, Thal L, Jin S, Jack C, Scheltens P (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64:108-115 (Pubitemid 46072432)
30. McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr, Holland D, Karow DS, Pung CJ, Brewer JB, Dale AM (2009) For the Alzheimer's disease neuroimaging initiative Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251:195-205
31. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, Barker W, Schofield E, Wu Y, Potter H (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71:1986-1992
32. Urs R, Potter E, Barker W, Appel J, Loewenstein DA, Zhao W, Duara R (2009) Visual rating system for assessing magnetic resonance images: a tool in the diagnosis of mild cognitive impairment and Alzheimer disease. J Comput Assist Tomogr 33:73-78
33. Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR. Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Borowski B, Shaw LM, Trojanowski JQ, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009) The Alzheimer's disease neuroimaging initiative Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates biomarkers and cognition. Neuroimage 45:645-655
34. Henneman WJ, Sluimer JD, Barnes J, van. der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H, Barkhof F (2009) Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72:999-1007
35. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Alzheimer's disease neuroimaging initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132:1355-1365
36. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones R, Bullock R, Love S, Neal J, Zotova E, Nicoll J (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223
37. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Medical research council cognitive function and ageing study. Age, neuropathology, and dementia. N Engl J Med 360:2302-2309
38. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376-388
39. Bennett DA, Schneider JA, Arvanitakis Z, Kelly J, Aggarwal N, Shah R, Wilson R (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837-1844 (Pubitemid 44049813)
40. Haroutunian. V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit D, Perl D, Libow L, Lesser G, Maroukian M, Grossman II (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65:1211-1217
41. SilverMH,NewellK,BradyC,Hedley-WhiteE,PerlsTT(2002) Distinguishingbetweenneurodegenerativediseaseanddisease-freeaging: correlatingneuropsychologicalevaluationsandneurapathologicalstudiesincentenaria ns.PsychosomMed64:493-501(Pubitemid34556415)
42. Ewbank DC, Arnold SE (2009) Cool with plaques and tangles. N Engl J Med 360:2357-2359
43. MamiyaT,UkaiM(2001)[Gly(14)]- Humaninimprovedthelearningandmemoryimpairmentinducedbyscopolamineinvivo. BrJPharmacol134:1597-1599(Pubitemid34038091)
44. Krejcova G, Patocka J, Slaninova J (2004) Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J Pept Sci 10:636-639 (Pubitemid 39409623)
45. Chiba T, Yamada M, Hashimoto Y, Sato M, Sasabe J, Kita Y, Terashita K, Aiso S, Nishimoto I, Matsuoka M (2005) Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci 25:10252-10261 (Pubitemid 41636222)
46. Tajima H, Kawasumi M, Chiba T, Yamada M, Yamashita K, Nawa M, Kita Y, Kouyama K, Aiso S, Matsuoka M, Niikura T, Nishimoto I (2005) A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J Neurosci Res 79:714-723 (Pubitemid 40476451)
47. Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M (2008) Nasal colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmaco 33:2020-2032
48. Miao J, Zhang W, Yin R, Liu. R, Su C, Lei G, Li Z (2008) S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. Neuropeptides 42:557-567
49. Kunesová G, Hlavácek J, Patocka J, Evangelou A, Zikos C, Benaki D, Paravatou-Petsotas M, Pelecanou M, Livaniou E, Slaninova J (2008) The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides 29:1982-1987
50. Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S (2009) Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry 14:206-222
51. Chiba T, Hashimoto Y, Tajima H, Yamada M, Kato R, Niikura T et al. (2004) Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SODl in vitro and in vivo. J Neurosci Res 78:542-552 (Pubitemid 39536498)
52. KariyaS,TakahashiN,OobaN,KawaharaM,NakayamaH,UenoS(2002) Humanininhibitscelldeathofserum-deprivedPC12hcells.NeuroReport13: 903-907(Pubitemid34492924)
53. Kariya S, Hirano M, Nagai Y, Furiya Y, Fujikake N, Toda T et al. (2005) Humanin attenuates apoptosis induced by DRPLA proteins with expanded polyglutamine stretches. J Mol Neurosci 25:165-169 (Pubitemid 41389357)
54. Xu X, Chua CC, Gao J, Hamdy RC, Chua BH (2006) Humanin is a novel neuroprotective agent against stroke. Stroke 37:2613-2619 (Pubitemid 44454687)
55. Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, Matsuoka M (2005) Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci 77:3092-3104 (Pubitemid 41423745)
56. Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC (2003) Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423:456-461 (Pubitemid 36626999)
57. YingG,IribarrenP,ZhouY,GongW,ZhangN,YuZX,LeY,CuiY,WangJM(2004)Humanin, anewlyidentifiedneuroprotectivefactor,usestheGprotein- coupledformylpeptidereceptor-like-1asafunctionalreceptor.JImmunol172: 7078-7085(Pubitemid38669150)
58. Taga T (1997) gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797-819
59. Heinrich C, Behrmann I, Haan S, Herrmanns H, Muller-newman G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20 (Pubitemid 37046923)
60. PflanzS,HibbertL,MattsonJ,RosalesR,VaisbergE,BazanJ,PhillipsJ, McClanahanT,deWaalMR,KasteleinR(2004)WSX-1andglycoprotein130constituteasignal- transducingreceptorforIL-27.JImmunol172:2225-2231(Pubitemid38182370)
61. TakedaA,HamanoS,YamanakaA,HanadaT,IshibashiT,MakTW,YoshimuraA, YoshidaH(2003)RoleofIL-27/WSX-1signalingforinductionofT- betthroughactivationofSTAT1duringinitialTh1commitment.JImmunol170: 4886-4890(Pubitemid36554716)
62. KamiyaS,OwakiT,MorishimaN,FukaiF,MizuguchiJ,YoshimotoT(2004) AnindispensableroleforSTATlinIL-27-inducedT- betexpressionbutnotproliferationofnaiveCD4+Tcells.JImmunol173: 3871-3877(Pubitemid39280750)
63. Lucas S, Ghilardi N, Li J, de Sauvage FD (2003) IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and. -independent mechanisms. Proc Natl Acad Sci USA 100:15047-15052
64. YoshimuraT,TakedaA,HamanoS,MiyazakiY,KinjyoI,IshibashiT,YoshimuraY, YoshidaH(2006)Two-sidedrolesofIL-27: inductionofTh1differentiationonnaiveCD4+Tcellsversussuppressionofproinflammato rycytokineproductionincludingIL23-inducedIL- 17onactivatedCD4+TcellspartiallythroughSTAT3-dependentmechanism.JImmunol177: 5377-5385(Pubitemid44527610)
65. Yoshida H, Yoshiyuki M (2008) Regulation of immune responses by interleukin-27. Immunol Rev 226:234-247
66. StahlN,DavisS,WongV,TagaT,KishimotoT,IpNY,YancopoulosGD(1993) Cross-linkingidentifiesleukemiainhibitoryfactor- bindingproteinasaciliaryneurotrophicfactorreceptorcomponent.JBiolChem268: 7628-7631(Pubitemid23120326)
67. DavisS,AldrichTH,StahlN,PanL,TagaT,KishimotoT,IpNY,YancopoulosGD(1993) LIFRbetaandgp130asheterodimerizingsignaltransducersofthetripartiteCNTFreceptor. Science260:1805-1808(Pubitemid23244206)
68. Elson GC, Lelievre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, Suard I, de Coignac AB, Delneste Y, Bonnefoy JY, Gauchat JF, Gascan H (2000) CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci 3:867-872
69. Derouet D, Rousseau F, Alfonsi F, Froger J, Hermann J, Barbier F, Perret D, Diveu C, Guillet C, Preisser L, Dumont A, Barbado M, Morel A, deLapeyriere O, Gasean H, Chevalier S (2004) Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA 101:4827-4832 (Pubitemid 38469162)
70. Niikura T, Yamada M, Chiba T, Aiso S, Matsuoka M, Nishimoto I (2004) Characterization of V642I-A.bPP-induced cytotoxicity in primary neurons. J Neurosci Res 77:54-62 (Pubitemid 38850055)
71. Hashimoto Y, Kurita M, Matsuoka M (2009) Identification of soluble WSX-1 not as a dominant-negative but as an alternative functional receptor subunit for an anti-Alzheimer's disease rescue factor Humanin. Biochem Biophys Res Commun 389:95-99
72. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita. Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 324:227-231 (Pubitemid 34493875)
73. Bodzioch M, Lapicka-Bodzioch K, Zapala B, Kamysz W, Kiec-Wilk B, Dembinska-Kiec A (2009) Evidence for potential functionality of nuclearly-encoded humanin isoforms. Genomics. 2 in press
74. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA (2008) Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7:483-493
75. Terashita K, Hashimoto Y, Niikura T, Tajima H, Yamagishi Y, Ishizaka M, Kawasumi M, Chiba T, Kanekura K, Yamada M, Nawa M, Kita Y, Aiso S, Nishimoto I (2003) Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer's disease-related neurotoxicity: functional potentiation by isomerization and. dimerization. J Neurochem 85:1521-1538 (Pubitemid 36702564)